As a mutation of Keap1 is uncommon, its mechanism in NSCLC remains unknown and may be associated with other Keap1-binding proteins that have antiapoptotic and proliferative functions, including prothymosin a (22). This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.